Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
dal-ACUTE: Phase III trial of dalcetrapib initiated within 1 week after acute coronary syndrome
2010-022529-14Phase 3Completed
- Sponsor
- Roche
- Start
- Dec 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronary arteriosclerosis and acute coronary syndrome (ACS) comparing dalcetrapib with placebo (2 arms). Primary endpoint: Primary efficacy endpoint: percent change in HDL-C at 4 weeks. Started Dec 2010; status: completed.
02
Drugs
dalcetrapib
03
Conditions
coronary arteriosclerosisacute coronary syndrome (ACS)
Beyond the preview
Go deeper on 2010-022529-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022529-14.